Challenges and Progress in the Treatment of Organ Damage Associated by ANCA or Life-threatening ANCA Associated Vasculitis

doi:10.12114/j.issn.1007-9572.2021.01.006

Abstract

Abstract: With the development of a large number of clinical studies and the release of national guidelines，the treatment of organ damage associated by ANCA and ANCA associated vasculitis （AAV） has made an important breakthrough，transforming it from a fatal disease into a chronic disease. The role of rituximab （RTX）in induction and maintenance therapy has been strongly supported by evidence-based medicine and it has finally been included in most of the current guidelines. Optimizing treatment drugs，treatment doses and treatment cycles，reducing adverse drug reactions，and ultimately improving patient survival rates are the directions of future clinical research.

Key words: Anti-neutrophil cytoplasmic antibody-associated vasculitis, Therapy, Immunosuppressive agents, Rituximab, Review, Guidebook

摘要： 随着大量临床研究的开展和各国指南的发布，伴有器官损害或威胁生命的ANCA相关性血管炎（AAV）的治疗已经获得了重要突破，从致死性疾病转变为一类慢性疾病。利妥昔单抗（RTX）在AAV诱导和维持治疗中的作用获得了有力的循证医学支持，并最终纳入现行的大部分指南。AAV患者的长期预后不仅取决于血管炎疾病本身，还取决于长期用药带来的不良反应。因此，优化治疗药物、治疗剂量和治疗周期，减少药物的不良反应，最终改善生存率是未来临床研究的工作方向。

HE Xu,XIA Zhengkun. Challenges and Progress in the Treatment of Organ Damage Associated by ANCA or Life-threatening ANCA Associated Vasculitis　[J]. Chinese General Practice, 2021, 24(23): 2891-2897. DOI: 10.12114/j.issn.1007-9572.2021.01.006.
何旭,夏正坤. 伴器官损害或威胁生命的ANCA相关性血管炎的治疗进展及挑战[J]. 中国全科医学, 2021, 24(23): 2891-2897. DOI: 10.12114/j.issn.1007-9572.2021.01.006.

References

［1］DE GROOT K，HARPER L，JAYNE D R，et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis：a randomized trial［J］. Ann Intern Med，2009，150（10）：670-680. DOI：10.7326/0003-4819-150-10-200905190-00004.
［2］STONE J H，MERKEL P A，SPIERA R，et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis［J］. N Engl J Med，2010，363（3）：221-232. DOI：10.1056/NEJMoa0909905.
［3］JONES R B，TERVAERT J W，HAUSER T，et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis［J］. N Engl J Med，2010，363（3）：211-220. DOI：10.1056/nejmoa0909169.
［4］NTATSAKI E，CARRUTHERS D，CHAKRAVARTY K，et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis［J］. Rheumatology （Oxford），2014，53（12）：2306-2309. DOI：10.1093/rheumatology/ket445.
［5］MCGEOCH L，TWILT M，FAMORCA L，et al. CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides［J］. J Rheumatol，2016，43（1）：97-120. DOI：10.3899/jrheum.150376.
［6］SOUZA A W S，CALICH A L，MARIZ H A，et al. Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis［J］. Rev Bras Reumatol Engl Ed，2017，57（Suppl 2）：484-496. DOI：10.1016/j.rbre.2017.06.003.
［7］YATES M，WATTS R A，BAJEMA I M，et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis［J］. Ann Rheum Dis，2016，75（9）：1583-1594.
［8］DE GRAEFF N，GROOT N，BROGAN P，et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative ［J］. Rheumatology（Oxford），2019，58（4）：656-671. DOI：10.1093/rheumatology/key322.
［9］GEETHA D，SPECKS U，STONE J H，et al.Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement［J］. J Am Soc Nephrol，2015，26（4）：976-985. DOI：10.1681/ASN.2014010046.
［10］UNIZONY S，VILLARREAL M，MILOSLAVSKY E M，et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody （ANCA）-associated vasculitis based on ANCA type［J］. Ann Rheum Dis，2016，75（6）：1166-1169. DOI：10.1136/annrheumdis-2015-208073.
［11］ JONES R B，FURUTA S，TERVAERT J W，et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis：2-year results of a randomised trial［J］. Ann Rheum Dis，2015，74（6）：1178-1182. DOI：10.1136/annrheumdis-2014-206404.
［12］SPECKS U，MERKEL P A，SEO P，et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis［J］. N Engl J Med，2013，369（5）：417-427. DOI：10.1056/NEJMoa1213277.
［13］CARTIN-CEBA R，GOLBIN J M，KEOGH K A，et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis （Wegener's）：ten-year experience at a single center［J］. Arthritis Rheum，2012，64（11）：3770-3778. DOI：10.1002/art.34584.
［14］ROCCATELLO D，SCIASCIA S，ROSSI D，et al. The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis：a 10 years observation study［J］. Oncotarget，2017，8（32）：52072-52077. DOI：10.18632/oncotarget.18120.
［15］ROCCATELLO D. “How I treat” autoimmune diseases：state of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis［J］. Autoimmun Rev，2017，16（10）：995-998. DOI：10.1016/j.autrev.2017.07.015.
［16］JONES R B，FERRARO A J，CHAUDHRY A N，et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis［J］. Arthritis Rheum，2009，60（7）：2156-2168. DOI：10.1002/art.24637.
［17］RHEE E P，LALIBERTE K A，NILES J L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis［J］. Clin J Am Soc Nephrol，2010，5（8）：1394-1400. DOI：10.2215/CJN.08821209.
［18］ROUBAUD-BAUDRON C，PAGNOUX C，MéAUX-RUAULT N，et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis［J］. J Rheumatol，2012，39（1）：125-130. DOI：10.3899/jrheum.110143.
［19］SMITH R M，JONES R B，GUERRY M J，et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis［J］. Arthritis Rheum，2012，64（11）：3760-3769. DOI：10.1002/art.34583.
［20］GUILLEVIN L，PAGNOUX C，KARRAS A，et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis［J］. N Engl J Med，2014，371（19）：1771-1780. DOI：10.1056/NEJMoa1404231.
［21］PAGNOUX C，HOGAN S L，CHIN H，et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis：comparison of two independent cohorts［J］. Arthritis Rheum，2008，58（9）：2908-2918. DOI：10.1002/art.23800.
［22］CALICH A L，PUéCHAL X，PUGNET G，et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis （Wegener's）. Results of a single-center cohort study on 66 patients［J］. J Autoimmun，2014，50：135-141. DOI：10.1016/j.jaut.2014.03.002.
［23］CHARLES P，TERRIER B，PERRODEAU é，et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission：results of a multicentre，randomised controlled，phase Ⅲ trial （MAINRITSAN2）［J］. Ann Rheum Dis，2018，77（8）：1143-1149. DOI：10.1136/annrheumdis-2017-212878.
［24］WALSH M，MERKEL P A，PEH C A，et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis （PEXIVAS）：protocol for a randomized controlled trial［J］. Trials，2013，14：73. DOI：10.1186/1745-6215-14-73.
［25］FURUTA S，SUGIYAMA T，UMIBE T，et al. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis （LoVAS）：protocol for a multicentre，open-label，randomised controlled trial［J］. BMJ Open，2017，7（12）：e018748. DOI：10.1136/bmjopen-2017-018748.
［26］JAYNE D R，GASKIN G，RASMUSSEN N，et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis［J］. J Am Soc Nephrol，2007，18（7）：2180-2188. DOI：10.1681/asn.2007010090.
［27］WALSH M，CASIAN A，FLOSSMANN O，et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear［J］. Kidney Int，2013，84（2）：397-402. DOI：10.1038/ki.2013.131.
［28］BESADA E，KOLDINGSNES W，NOSSENT J C. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis：results from a single centre［J］. Rheumatology：Oxford，2013，52（11）：2041-2047. DOI：10.1093/rheumatology/ket257.
［29］GOPALUNI S，SMITH R M，LEWIN M，et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis （RITAZAREM）：study protocol for a randomized controlled trial［J］. Trials，2017，18（1）：112. DOI：10.1186/s13063-017-1857-z.
［30］KARRAS A，PAGNOUX C，HAUBITZ M，et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis［J］. Ann Rheum Dis，2017，76（10）：1662-1668. DOI：10.1136/annrheumdis-2017-211123.

[1]	HE Yang, YANG Rong, SHEN Can, YI Shanye, LIU Lidi, ZHAO Qian, WAN Zhi, LIAO Xiaoyang. Progress in Research on the Trajectory of Frailty and Its Influencing Factors [J]. Chinese General Practice, 2026, 29(30): 4372-4378.
[2]	GUO Zhihong, CHEN Yingying, LIU Dewu. Efficacy and Safety of Antibiotic Bone Cement Combined with Vacuum Sealing Drainage for Diabetic Foot: a Meta-analysis [J]. Chinese General Practice, 2026, 29(30): 4503-4512.
[3]	ZHAO Jiayi, FAN Jian, YU Dehua. The Current Situation, Challenges, and Coping Strategies of Preserving Ratio Impaired Spirometry [J]. Chinese General Practice, 2026, 29(30): 4366-4371.
[4]	LI Lan, LIU Lidi, ZHANG Peng, LI Dongze, YANG Ziyu, CHENG Yonglang, LIAO Xiaoyang, WAN Zhi. Lifestyle Intervention-based Weight Management: an Analysis of Key Highlights from the Partial Update of the 2025 NICE Guideline Overweight and Obesity Management (NG246) [J]. Chinese General Practice, 2026, 29(30): 4353-4359.
[5]	LI Xiling, ZHANG Fan, YANG Xinyue, YANG Heng. Application of Exercise Snacks in Chronic Disease Management: a Scoping Review [J]. Chinese General Practice, 2026, 29(30): 4472-4479.
[6]	WANG Dunjian, CHEN Yonggang, HU Bing, ZHAO Hengyi, YANG Qing. Application of Home-based Medication Therapy Management in Contracted Patients with Diabetes and Hypertension: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(29): 4226-4231.
[7]	CHEN Yujing, WANG Yan, LI Guang, DONG Benchao, YANG Peichuan, MA Jianxiong. Digital Technologies in the Management of Sarcopenia among Older Adults in Asia: a Scoping Review [J]. Chinese General Practice, 2026, 29(29): 4200-4210.
[8]	SHI Li, ZHOU Zhenkun, LIU Jie, PAN Guofeng. A Randomized Controlled Trial of Sinew Meridian Theory-based Combined Acupuncture and Cupping Therapy for Postmenopausal Women with Stress Urinary Incontinence [J]. Chinese General Practice, 2026, 29(28): 4141-4146.
[9]	XIE Xiaoyun, LIU Chenxi, LIU Yushu, ZHOU Yihan. Artificial Intelligence Research Practices in Primary Healthcare Institutions in China and the Potential Issue of Data Poverty: a Scoping Review [J]. Chinese General Practice, 2026, 29(28): 4067-4077.
[10]	FENG Yachen, LIU Lewei, XUE Jinyue, SUN Xianlin, LIU Huanzhong. Research Progress of Wearable Technology in the Diagnosis and Treatment of Mental Disorders [J]. Chinese General Practice, 2026, 29(27): 4016-4025.
[11]	CHEN Jingjing, BAI Xinyuan, SHA Huizi, SUN Yi, NI Jiayao, TONG Fan, ZOU Lu, MENG Fanyan, DU Juan. Analysis of the Efficacy and Safety of Gemcitabine plus S-1 Regimen versus S-1 Combined with Oxaliplatin and Irinotecan Regimen as Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma [J]. Chinese General Practice, 2026, 29(26): 3767-3773.
[12]	WANG Shuangrui, WANG Yongjia, FAN Xiaomin, LIU Xiangyu, HU Shunqing, YANG Zijian, ZHANG Xinjian. Efficacy and Safety of High-frequency Versus Low-frequency Stellate Ganglion Block Combined with Cognitive Behavioral Therapy for Insomnia in the Treatment of Insomnia Disorder [J]. Chinese General Practice, 2026, 29(25): 3678-3685.
[13]	LIU Yahui, XU Yanan, YUAN Ling, WU Ligui, ZHOU Yujie, KANG Yubiao. A Scoping Review on Triage for Palliative Care Patients Based on Priority Decision-making [J]. Chinese General Practice, 2026, 29(24): 3538-3544.
[14]	WANG Rui, LUO Shuoming, YANG Liang, WANG Peng, ZHAO Yang, WANG Qi, ZHOU Zhiguang. Diabetes Prevalence among Older Adults in China: a Systematic Review and Meta-analysis [J]. Chinese General Practice, 2026, 29(24): 3500-3508.
[15]	WU Liyun, SUN Huajing, GU Yiqing, MEI Ziqi, JIN Shengji, ZHANG Suju, ZHU Yun, ZHANG Yao, LI Qin, LIU Xiaomiao, WANG Qing, BAI Yamei, XU Guihua. Application of Digital-intelligent Technology in Electrocardiographic Monitoring for Acute Myocardial Infarction: a Scoping Review [J]. Chinese General Practice, 2026, 29(24): 3545-3552.